FDA NEWS.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 12, p. 23
- Publication type:
- Article
Works matching IS 21644403 AND DT 2023 AND VI 13 AND IP 12
Results: 8
1
2
Select Ongoing Trials Currently Enrolling Patients With Bladder Cancer.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 12, p. 20
- Publication type:
- Article
3
Leading When Exhaustion Sets In.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 12, p. 18
- By:
- Publication type:
- Article
4
Phase 3 Trials Show Superiority of Targeted Treatments Over Chemotherapy in Oncogene-Addicted NSCLC.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 12, p. 9
- By:
- Publication type:
- Article
5
The Crucial Role of Financial Navigators in Oncology.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 12, p. 1
- By:
- Publication type:
- Article
6
Selpercatinib Improves Outcomes in RET Mutation--Positive Medullary Thyroid Cancer.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 12, p. 7
- By:
- Publication type:
- Article
7
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 12, p. 1
- By:
- Publication type:
- Article
8
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 12, p. 1
- By:
- Publication type:
- Article